Skip to main content
NVDA+0.06%AAPL-0.17%GOOGL+0.97%MSFT-0.03%AMZN+0.02%TSM-1.02%SPCX+1.25%META-0.15%AVGO+0.39%TSLA+0.04%SKHY-0.86%MU+0.02%BRK-B+0.86%LLY+0.83%AMD-2.03%JPM+0.47%WMT+0.71%V+2.76%XOM+0.26%ASMLa-0.07%JNJ+1.93%INTC-2.22%MA+2.50%0700.HK+3.26%ABBV+1.49%CSCO+3.05%1398.HK-0.92%CVX+0.20%COST-0.11%ORCL+4.30%AP2d-0.05%AMAT-0.50%LRCX-0.55%DELL+2.04%BAC+1.32%KO+0.32%CAT+0.54%PG+0.42%UNH+2.25%3988.HK+1.66%1816.HK+0.45%0005.HK+1.82%GE+0.84%HSBA.L0.00%PM+0.34%0857.HK0.00%0939.HK+0.83%MS+1.38%NFLX-1.77%1288.HK-1.52%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%EURSEK0.00%CADJPY0.00%GBPNZD0.00%CADCHF0.00%USDDKK0.00%GBPCHF0.00%GBPUSD0.00%GBPCAD0.00%USDPLN0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDCAD0.00%NZDMXN0.00%EURCAD0.00%CHFJPY0.00%EURUSD0.00%EURJPY0.00%EURNZD0.00%GBPAUD0.00%EURNOK0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%AUDCHF0.00%USDSGD0.00%EURDKK0.00%NZDJPY0.00%USDZAR0.00%USDHKD0.00%GBPSGD0.00%GBPZAR0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.30%ETHUSD+15.73%USDTUSD+0.01%XRPUSD+7.53%SOLUSD+8.55%TRXUSDT-0.21%ZECUSDT+2.40%DOGEUSD+9.80%XMRUSDT+1.90%LINKUSD+11.71%XLMUSD+1.44%BCHUSDT+0.88%LTCUSD+5.41%UNIUSD+2.08%SUIUSD+3.59%HBARUSDT+0.43%TONUSD+17.89%TAOUSDT+2.86%AAVEUSD+4.48%DOTUSDT+0.95%ICPUSDT+2.96%ONDOUSDT+3.54%WLDUSDT+15.58%JUPUSDT-0.36%ARBUSDT+1.13%ATOMUSDT-6.11%STXUSDT+1.24%INJUSDT+1.85%FETUSDT+4.43%PYTHUSDT-1.05%SEIUSDT+1.92%TIAUSDT+3.30%IMXUSDT-0.66%GRTUSDT-0.32%OPUSDT+3.88%IOTAUSDT+3.97%WIFUSDT+0.60%AXSUSDT+4.53%POLUSDT-0.12%FARTCOINUSDT+3.14%EOSUSDT+9.07%DYDXUSDT+0.57%GALAUSDT+3.13%ORDIUSDT+5.96%RONINUSDT+10.14%NOTUSDT+6.90%NVDA+0.06%AAPL-0.17%GOOGL+0.97%MSFT-0.03%AMZN+0.02%TSM-1.02%SPCX+1.25%META-0.15%AVGO+0.39%TSLA+0.04%SKHY-0.86%MU+0.02%BRK-B+0.86%LLY+0.83%AMD-2.03%JPM+0.47%WMT+0.71%V+2.76%XOM+0.26%ASMLa-0.07%JNJ+1.93%INTC-2.22%MA+2.50%0700.HK+3.26%ABBV+1.49%CSCO+3.05%1398.HK-0.92%CVX+0.20%COST-0.11%ORCL+4.30%AP2d-0.05%AMAT-0.50%LRCX-0.55%DELL+2.04%BAC+1.32%KO+0.32%CAT+0.54%PG+0.42%UNH+2.25%3988.HK+1.66%1816.HK+0.45%0005.HK+1.82%GE+0.84%HSBA.L0.00%PM+0.34%0857.HK0.00%0939.HK+0.83%MS+1.38%NFLX-1.77%1288.HK-1.52%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%EURSEK0.00%CADJPY0.00%GBPNZD0.00%CADCHF0.00%USDDKK0.00%GBPCHF0.00%GBPUSD0.00%GBPCAD0.00%USDPLN0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDCAD0.00%NZDMXN0.00%EURCAD0.00%CHFJPY0.00%EURUSD0.00%EURJPY0.00%EURNZD0.00%GBPAUD0.00%EURNOK0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%AUDCHF0.00%USDSGD0.00%EURDKK0.00%NZDJPY0.00%USDZAR0.00%USDHKD0.00%GBPSGD0.00%GBPZAR0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.30%ETHUSD+15.73%USDTUSD+0.01%XRPUSD+7.53%SOLUSD+8.55%TRXUSDT-0.21%ZECUSDT+2.40%DOGEUSD+9.80%XMRUSDT+1.90%LINKUSD+11.71%XLMUSD+1.44%BCHUSDT+0.88%LTCUSD+5.41%UNIUSD+2.08%SUIUSD+3.59%HBARUSDT+0.43%TONUSD+17.89%TAOUSDT+2.86%AAVEUSD+4.48%DOTUSDT+0.95%ICPUSDT+2.96%ONDOUSDT+3.54%WLDUSDT+15.58%JUPUSDT-0.36%ARBUSDT+1.13%ATOMUSDT-6.11%STXUSDT+1.24%INJUSDT+1.85%FETUSDT+4.43%PYTHUSDT-1.05%SEIUSDT+1.92%TIAUSDT+3.30%IMXUSDT-0.66%GRTUSDT-0.32%OPUSDT+3.88%IOTAUSDT+3.97%WIFUSDT+0.60%AXSUSDT+4.53%POLUSDT-0.12%FARTCOINUSDT+3.14%EOSUSDT+9.07%DYDXUSDT+0.57%GALAUSDT+3.13%ORDIUSDT+5.96%RONINUSDT+10.14%NOTUSDT+6.90%
PE

Penumbra, Inc. (PEN)

NYSE • Healthcare

$319.39
+$1.87 (+0.6%)
Market closed

Last close at October 9, 2026 at 20:00 UTC

Open$317.06
Day Range$317.06 - $319.53
Avg. Volume (3M)413.7K
Market Cap$12.5B
P/E Ratio78.1
52 Week Range
$221.26$362.41
Next EarningsIn 25 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$390M100%
Gross Profitminus cost of goods$264.9M68%
Operating Incomeminus R&D and overhead$41M11%
Net Incomeminus taxes and the rest$34.8M9%

In plain terms: out of every $100 in revenue, Penumbra, Inc. keeps $9 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1.5B
Net Income (TTM)
$160.5M
EPS (TTM)
$4.09
ROA (TTM)
8.13%
Current Ratio
5.75

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+6.3%Q1 2026$1.18
-21.2%Q2 2026$0.82
-24.1%Q3 2026$0.88
Next

Nov 4

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -24.1%

Penumbra’s second fiscal quarter of 2026, reported July 30, 2026, was a mixed print: EPS of $0.88 missed the $1.16 estimate by about 24%, even as revenue of about $390.0 million edged the $389.6 million consensus by roughly 0.1%. Revenue rose about 15% from $339.5 million a year ago, and gross margin held near 68% while operating margin came in around 11%, with gross profit at about $264.9 million and operating income of roughly $41.0 million. Net income fell about 23% to roughly $34.8 million from $45.3 million a year ago, while operating cash flow was $46.1 million. Consensus for the next period calls for EPS of $1.26 on revenue of $401.5 million.

Next report — what to expect

Penumbra, Inc. (PEN) reports on November 4, 2026. Wall Street is looking for EPS of $1.20 on revenue of $401.4 million. For trailing context, revenue grew +14.9% year over year last quarter. PEN has beaten EPS in 6 of 8 most recent quarters, keeping focus on margins and procedure-driven demand.

View full earnings history

About Penumbra, Inc.

Penumbra, Inc. develops and sells medical technology for vascular and neuro interventions, trading on the NYSE as PEN. In healthcare, it focuses on devices used to remove clots, treat aneurysms and other lesions, and support neurosurgical evacuation, with $1.4 billion in FY2025 revenue.

Name
Penumbra, Inc.
CEO
Adam Elsesser
Industry
Healthcare
Year Founded
2004
Employees
4,700

Today's Snapshot

AI-generated

PEN closed 0.6% above yesterday's close, in line with a firmer sector. Shares changed hands at about half as much again as its usual level.

Trading Volume

Above 10d avg 329.4K

524.1K

vs S&P 500 Today

Inline with Market

+0.00%

Updated: October 9, 2026 at 20:12 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
PEN’s profile leans mildly bullish as the stock trades just above its 10- and 20-day averages and sits slightly above the pivot at 317, while longer-term signals are mixed with the 200-day measures not decisively above price. Trend strength is modest with ADX near 21, and momentum indicators are neutral to slightly positive — RSI around 52 and short-term momentum positive while MACD remains near zero. Volatility is low with ATR about 0.5%, although OBV shows limited distribution. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$317.10 - $320.16
    Buy
  • RSI (14)51.76
    Neutral
  • Stochastic %K (14, 3, 3)36.37
    Neutral
  • MACD Level (12, 26)-0.85
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.